AUROPHARMA:NSE-Aurobindo Pharma Limited (INR)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSE

Last Closing Price

INR 772.10

Change

0.00 (0.00)%

Market Cap

INR 452.40B

Volume

4.84M

Average Target Price

INR 771.63 (-0.06%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of various pharmaceutical products in India. The company primarily offers oral solids, injectables, over the counter drugs, and dietary supplements, as well as active pharmaceutical ingredients and finished dosage forms for central nervous system, cardiovascular, anti-retroviral, anti-diabetics, anti-allergies, gastroenterology, antibiotics, dermatology, respiratory, and oncology, as well as specialty generic formulations. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, transdermal patches, inhalers, vaccines, and depot injections. The company also exports its products to approximately 155 countries. It serves multinational companies. The company was founded in 1986 and is headquartered in Hyderabad, India. Address: Water Mark Building, Hyderabad, India, 500084

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-26 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

N/A

INR1,174.83B 160.86 32.48
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

N/A

INR848.57B 44.75 26.36
DIVISLAB:NSE Divi's Laboratories Limited

N/A

INR809.95B 50.23 34.27
LUPIN:NSE Lupin Limited

N/A

INR452.63B 49.28 27.33
CADILAHC:NSE Cadila Healthcare Limited

N/A

INR394.39B 29.06 16.74
ALKEM:NSE Alkem Laboratories Limited

N/A

INR335.06B 24.10 18.33
IPCALAB:NSE Ipca Laboratories Limited

N/A

INR261.69B 28.38 19.52
APLLTD:NSE Alembic Pharmaceuticals Limite..

N/A

INR188.56B 17.42 14.41
NATCOPHARM:NSE NATCO Pharma Limited

N/A

INR161.59B 35.29 23.75
LAURUSLABS:NSE Laurus Labs Limited

N/A

INR142.32B 33.48 19.84

ETFs Containing AUROPHARMA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 68.54% 60% D- 92% A-
Dividend Return 0.27% 43% F 21% F
Total Return 68.82% 60% D- 92% A-
Trailing 12 Months  
Capital Gain 29.29% 27% F 79% C+
Dividend Return 0.42% 44% F 29% F
Total Return 29.71% 27% F 79% C+
Trailing 5 Years  
Capital Gain 3.39% 40% F 58% F
Dividend Return 1.61% 38% F 15% F
Total Return 4.99% 40% F 56% F
Average Annual (5 Year Horizon)  
Capital Gain -4.62% N/A N/A 41% F
Dividend Return 0.34% N/A N/A 25% F
Total Return -4.28% N/A N/A 41% F
Risk Return Profile  
Volatility (Standard Deviation) 21.58% N/A N/A 88% B+
Risk Adjusted Return -19.84% N/A N/A 35% F
Market Capitalization 452.40B 94% A 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 15.36 74% C 50% F
Price/Book Ratio 2.72 59% F 24% F
Price / Cash Flow Ratio 10.33 63% D 30% F
EV/EBITDA 9.59 75% C 54% F
Management Effectiveness  
Return on Equity 18.43% 77% C+ 83% B
Return on Invested Capital 13.92% 70% C- 83% B
Return on Assets 8.89% 79% C+ 88% B+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.75 58% F 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector